EPA: ABLD Company Description

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally.

It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation system, and sanger sequencing reagents.

The company also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB.

It sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers.

The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics Société anonyme in April 2022.

The company is based in Woippy, France. ABL Diagnostics Société anonyme is a subsidiary of Advanced Biological Laboratories (ABL) S.A.

ABL Diagnostics Société anonyme

Country	France
Industry	Health Information Services
Sector	Healthcare
Employees	20
CEO	Chalom Sayada

Contact Details

Address: 72c, rue de Thionville Woippy, 57140 France
Phone	33 3 87 17 81 56
Website	abldiagnostics.com

Stock Details

Ticker Symbol	ABLD
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR001400AHX6
SIC Code	9998

Key Executives

Name	Position
Dr. Chalom B. Sayada M.D., Ph.D.	GM and Director
Ronan Boulme	Director of Regulatory Affairs